Copyright
©The Author(s) 2023.
World J Orthop. Jun 18, 2023; 14(6): 485-501
Published online Jun 18, 2023. doi: 10.5312/wjo.v14.i6.485
Published online Jun 18, 2023. doi: 10.5312/wjo.v14.i6.485
Ref. | Sample size (I/C) | Achilles tendon lesion | Location | Control | Follow-up | PRP injection frequency/interval/dose (mL) |
de Vos et al[42], 2010 | 27/27 | C-AT (> 2 mo) | Netherlands | Saline | 6, 12, 24 wk | Once/-/4 |
de Jonge et al[41], 2011 | 27/27 | C-AT (> 2 mo) | Netherlands | Saline | 6, 12, 24, 48 wk | Once/-/4 |
Kearney et al[50], 2013 | 9/10 | C-AT (> 8 mo) | United Kingdom | Blank | 6 wk, 3 mo, 6 mo | Once/-/3 to 5 |
Krogh et al[22], 2016 | 12/12 | C-AT (mean 33 mo) | Denmark | Saline | 3, 6, 12 mo | Once/-/6 |
Boesen et al[21], 2017 | 19/19 | C-AT (> 3 mo) | Denmark | Saline | 6, 12, 24 wk | 4 times/2-wk/4 |
van der Vlist et al[53], 2020 | 39/41 | C-AT (> 6 mo) | Netherlands | Saline | 2, 6, 12, 24 wk | Once/-/NR |
Thermann et al[51], 2020 | 17/19 | C-AT (> 6 mo) | Italy | Blank | 6 wk, 3, 6, 12 mo | Once/-/NR |
Kearney et al[52], 2021 | 121/119 | C-AT (> 3 mo) | United Kingdom | Blank | 2 wk, 3, 6 mo | Once/-/3 |
Schepull et al[28], 2011 | 15/14 | A-ATR (< 3 d) | Sweden | Blank | 6, 12 mo | Once/-/10/4 |
De Carli et al[49], 2015 | 15/15 | A-ATR | Italy | Blank | 1, 3, 6, 24 mo | 2 times/2-wk/4 |
Zou et al[27], 2016 | 16 /20 | A-ATR (< 3 wk) | China | Placebo | 3 wk, 3, 6, 12, 24 mo | Once/-/NR |
Keene et al[33], 2019 | 107/109 | A-ATR (< 12 d) | United Kingdom | Placebo | 4, 7, 13, 24 wk | Once/-/4 |
Boesen et al[34], 2020 | 19/19 | A-ATR (< 3 d) | Denmark | Saline | 8 wk, 3, 6, 12 mo | Once/-/4 |
- Citation: Huang D, Vithran DTA, Gong HL, Zeng M, Tang ZW, Rao ZZ, Wen J, Xiao S. Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease. World J Orthop 2023; 14(6): 485-501
- URL: https://www.wjgnet.com/2218-5836/full/v14/i6/485.htm
- DOI: https://dx.doi.org/10.5312/wjo.v14.i6.485